Month: February 2021

伊利诺伊州威尔梅特, Feb. 11, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布其一篇同行评议研究的论文在《European Journal of Cancer》（欧洲癌症杂志）上发表，展示了MNPR-101作为uPAR显像剂在改善膀胱癌手术预后方面的应用潜力。使用Monopar专有的人源化uPAR抗体MNPR-101开发了一种多模态成像探针，并在人膀胱癌模型中进行了体内测试。 这篇论文报告说，uPAR在膀胱癌中的高表达位于肿瘤周围，表明使用荧光偶联的MNPR-101探针可能使外科医生更好地观察肿瘤边界，从而可能得到更完整的肿瘤切除，以此减少复发。相似的方法已成功用于乳腺癌等其他类型肿瘤的切除。膀胱癌通常通过经尿道切除术切除癌组织进行治疗。但是，高达78%的患者会在5年内复发。高达40%的复发病例会发展成肌层浸润性病变，预后较差，需要完全切除膀胱。遗憾的是，许多患有肌层浸润性膀胱癌的患者继续发展并死于转移性病变。“这种基于MNPR-101的新颖显像剂在让外科医生能够在手术过程中轻松识别肿瘤边缘方面很有利用前途。”Monopar首席科学官、该文合作作者Andrew Mazar博士表示， “鉴于uPAR在膀胱癌相对于正常膀胱组织中的表达特异性以及在肿瘤边界处的高表达，我们相信使用MNPR-101靶向成像uPAR可以改善手术效果，并可能减少疾病的复发。”莱顿大学（LUMC）医学中心影像引导外科小组成员、研究的主要研究者Cornelis Sier博士说：“如果在临床环境中得到证实，基于MNPR-101的成像探头可能会导致范例转变，从而改变泌尿科医师调查和治疗膀胱癌的方式。”关于Monopar Therapeutics Inc.Monopar Therapeutics是一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。Monopar处于不同研发阶段的产品包括：用于预防口咽癌症患者因化疗引起严重口腔黏膜炎的Validive®；用于治疗晚期软组织肉瘤的camsirubicin；以及用于晚期癌症和重症新冠肺炎的后期临床前抗体MNPR-101。如需获取更多信息，请访问：www.monopartx.com。前瞻性声明本新闻稿所载关于非历史事实事项的声明属于1995年《私人证券诉讼改革法案》中所述的“前瞻性声明”。“可能”、“将会”、“能够”、“将要”、“应该”、“预料”、“计划”、“预期”、“意在”、“相信”、“估计”、“预示”、“预测”、“潜在”、“继续”、“目标”和类似表达旨在标示前瞻性声明，但并非所有前瞻性声明都包含这些标示词。这些前瞻性声明的例子包括有关MNPR-101作为uPAR显像剂的应用潜力、基于MNPR-101的显像剂是否可以改善膀胱癌手术预后及相关问题的声明。前瞻性声明所涉及的风险和不确定因素包括但不限于：到目前为止缺乏任何关于MNPR-101的临床工作，到目前为止临床前开发活动一直专注于治疗癌症，重点并不在医疗器械上；完成采用MNPR-101的医疗器械的临床前和临床开发以及（开发成功后）商业化推广需要的额外资本；如果资金到位，无法开发MNPR-101作为治疗膀胱癌或任何其他癌症的uPAR显像剂使用；无法确保可以生产出足够数量的uPAR结合物并扩大规模以满足潜在需求；医疗器械一旦可供商业化生产时无法确定需求水平；以及关于医疗器械研究、开发、监管批准和治疗方法商业化等各种重大的综合风险和不确定性。实际结果可能与此类前瞻性声明中明示或暗示的结果存在重大差异。在Monopar向证券交易委员会提交的文件中，针对各种风险提供了更全面的描述。本新闻稿中包含的所有前瞻性声明仅适用于截至声明发布之日的情形。Monopar没有义务更新此类声明以反映声明作出后发生的事件或存在的情况。本新闻稿中包含的任何前瞻性声明仅代表Monopar截至本文日期的观点，不应被视为代表其后任何日期的意见。联系方式：Monopar...

MCLEAN, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today reported its fourth quarter and full-year 2020 financial results and filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (SEC). The company’s Form 10-K and press release are available now on its website, www.FreddieMac.com/investors, along with the fourth quarter 2020 financial results supplement.The company will hold a call at 9 a.m. Eastern Time (ET) on Thursday, Feb. 11, 2021, to share its results with the media. The call will be concurrently webcast, and the replay will be available on the company’s website at http://www.FreddieMac.com/investors for approximately 30 days.Freddie Mac makes home possible for millions of families and individuals by providing mortgage capital to lenders. Since our creation by Congress...

VAUGHAN, Ontario, Feb. 11, 2021 (GLOBE NEWSWIRE) — Ignite International Brands, Ltd. (CSE: BILZ, OTCQX: BILZF) (“IGNITE” or the “Company”), a global consumer packaged goods brand, today announced the launch of its highly anticipated IGNITE Spirits vodka. The vodka, previously available only to guests at private IGNITE events, can now be purchased through the Company’s partner ReserveBar. Quantities are limited as IGNITE Spirits are meticulously crafted with quality at the forefront of production.“Our vodka brings forth a fundamental shift to the spirits industry,” said IGNITE CEO Dan Bilzerian. “A good spirit can stand on its own with a taste that doesn’t require calorie-filled mixers to mask the flavor. The end result is a pure, undiluted experience that leaves our consumers satisfied.”“IGNITE customers...

MISSISSAUGA, Ontario, Feb. 11, 2021 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for the first quarter of its fiscal 2021, the three-months ended December 31, 2020 (“Q1”), with record sales and continued progress upon its strategic goals.Management DiscussionQ1 results are demonstrating the diagnostics sector uptake of Microbix’s innovative, proprietary, and branded test quality assessment products (“QAPs™”). Overall QAPs sales for Q1 increased nearly 3,600% from the same period in fiscal 2020 (“Q1 2020”), approaching $1.0 million and attaining a record 30% of Microbix’s total sales of $3.16 million. Microbix’s changing sales mix, along with strong operational discipline across all products, help improve gross margin and enable a positive...

MONACO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Eneti Inc. (NYSE: NETI) (the “Company”) announced today that the Company has entered into an agreement with an unaffiliated third party to sell the SBI Thalia and SBI Athena, Ultramax bulk carriers built in China in 2015, and SBI Perseus, SBI Pisces and SBI Hercules, Ultramax bulk carriers built in China in 2016, for approximately $88 million. The transaction remains subject to definitive documentation and delivery of the vessels is expected to take place in the second quarter of 2021.About Eneti Inc.Eneti Inc. announced on August 3, 2020, its intention to transition away from the business of dry bulk commodity transportation and towards marine-based renewable energy including investing in the next generation of wind turbine installation vessels. The Company intends to sell or have commitments...

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve” or the “Company”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce that it has signed a binding letter of intent to acquire 100% of Karland Health, LLC. In 2020, Medivolve’s wholly owned subsidiary, Collection Sites LLC, launched COVID-19 testing services in conjunction with Alcala Testing and Analysis Services, a CLIA registered high complexity laboratory based in San Diego, California. Collection Sites opened their first testing location on August 8, 2020 and has grown substantially since with January tests conducted of 73,973 at an average price of US$96 per test. Appointments and payments are handled through an online portal www.testbeforeyougo.com.Under the terms set out in the agreement, Medivolve is to issue a total of 20 million Medivolve common shares...

BOCA RATON, Fla., Feb. 11, 2021 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) will release its fourth quarter and full year 2020 financial results after the close of trading on Thursday, Feb. 25, 2021. Following the release, management will host a conference call at 5:00 pm ET to discuss the financial results and other related matters. The conference call can be accessed as follows:By dialing 1-877-407-3982 (domestic) or 1-201-493-6780 (international) and requesting the ADT Fourth Quarter 2020 Earnings Conference CallLive webcast accessed through ADT’s website at investor.adt.comAn audio replay of the conference call will be available from approximately 8:00 p.m. ET on Feb. 25, 2021, until 11:59 p.m. ET on March 11, 2021, and can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international), and providing the passcode,...

EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) — Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update conference call and webcast after the market close, on Thursday, February 25, 2021, at 4:30 PM Eastern Time.About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with...

To Nasdaq Copenhagen11 February 2021Nykredit Realkredit A/S publishes supplement no 2 to Base Prospectus dated 13 May 2020Nykredit Realkredit A/S publishes supplement no 2 to Base Prospectus dated 13 May 2020 for the issuance of CRD-compliant covered bonds, UCITS-compliant covered bond and bonds issued in pursuance of section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act.  Nykredit Realkredit A/S’s Base Prospectus dated 13 May 2020 and supplement are available for download in Danish and English. In the event of discrepancies between the original Danish text and the English translation, the Danish text shall prevail. The Base Prospectus and the supplement can be found on Nykredit’s website at nykredit.com/ir.Questions may be addressed to Group Treasury, Morten Bækmand Nielsen, Head of Investor Relations,...